Vergent Bioscience Completes Enrollment in Phase 2 VISUALIZE Trial Evaluating Potential of Abenacianine for Injection (VGT-309) to Improve Tumor Visualization During Cancer SurgeryBusiness Wire • 11/13/24
5 Low-Cost Vanguard ETFs That Just Surged to All-Time Highs After the ElectionThe Motley Fool • 11/12/24
1 Unstoppable Vanguard ETF That Could Turn $1,000 Into $143,000 or More With Next to No EffortThe Motley Fool • 11/05/24
Vanguard Information Technology ETF: 3 Reasons Why Investors Need to Own VGT Right Now24/7 Wall Street • 10/30/24
2 Terrific Growth ETFs to Buy Before 2025 That Aren't Schwab US Dividend ETF24/7 Wall Street • 10/25/24
This Vanguard ETF Has Generated 620% Returns in 10 Years. Is It Still a Buy?The Motley Fool • 10/20/24
1 Vanguard Index Fund to Buy to Beat the S&P 500 as the Artificial Intelligence (AI) Boom UnfoldsThe Motley Fool • 10/18/24
Meet The Low-Cost Vanguard ETF That Has 20% Of Its Holdings in Nvidia, Broadcom, and AMDThe Motley Fool • 10/17/24
This Superstar ETF Could Turn $200 per Month Into $1.3 Million. Here's How.The Motley Fool • 10/15/24
1 Supercharged Vanguard ETF That Can Turn $250 a Month Into $670,000 or More in 25 YearsThe Motley Fool • 10/03/24